Al-Rabadi Laith, Box Terry, Singhania Girish, Al-Marji Catreena, Agarwal Adhish, Hall Isaac, Gordon Craig E, Tran Huy
Renal Section, Department of Medicine, University of Utah Hospital, Salt Lake City, Utah, USA.
Gastroenterology Section, Department of Medicine, University of Utah Hospital, Salt Lake City, Utah, USA.
Hemodial Int. 2018 Apr;22 Suppl 1:S45-S52. doi: 10.1111/hdi.12656.
Hepatitis C virus (HCV) infection is a common problem in patients treated with maintenance hemodialysis (HD) and is associated with an increased morbidity and mortality and lower quality of life. The major causes of HCV-associated mortality are liver and cardiovascular-related death. HCV-infected HD patients have a higher prevalence of inflammation-related metabolic and vascular diseases, leading to high rates of cardiovascular mortality in patients with end-stage renal disease. In the current era of highly effective direct-acting antiviral regimens, HCV treatment may also confer hepatic, cardiovascular and other morbidity and mortality benefits even to dialysis-dependent patients who do not qualify for kidney transplantation. Currently, the most accepted regimens in this patient population include elbasvir/grazoprevir and glecaprevir/pibrentasvir.
丙型肝炎病毒（HCV）感染是维持性血液透析（HD）患者中的常见问题，与发病率和死亡率增加以及生活质量降低相关。HCV相关死亡的主要原因是肝脏和心血管相关死亡。HCV感染的HD患者炎症相关的代谢和血管疾病患病率较高，导致终末期肾病患者心血管死亡率较高。在当前高效直接作用抗病毒方案的时代，即使对于不符合肾移植条件的依赖透析的患者，HCV治疗也可能带来肝脏、心血管和其他方面发病率和死亡率的益处。目前，该患者群体中最被认可的方案包括艾尔巴韦/格拉瑞韦和格卡瑞韦/哌仑他韦。
